[go: up one dir, main page]

TW201909925A - 核酸複合體 - Google Patents

核酸複合體 Download PDF

Info

Publication number
TW201909925A
TW201909925A TW107126969A TW107126969A TW201909925A TW 201909925 A TW201909925 A TW 201909925A TW 107126969 A TW107126969 A TW 107126969A TW 107126969 A TW107126969 A TW 107126969A TW 201909925 A TW201909925 A TW 201909925A
Authority
TW
Taiwan
Prior art keywords
compound
nucleic acid
equation
reference example
mmol
Prior art date
Application number
TW107126969A
Other languages
English (en)
Chinese (zh)
Inventor
山田陽史
牧野麻奈
長谷川尚
岩井宏徒
上原啓嗣
鈴木康裕
Original Assignee
日商協和醱酵麒麟有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商協和醱酵麒麟有限公司 filed Critical 日商協和醱酵麒麟有限公司
Publication of TW201909925A publication Critical patent/TW201909925A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107126969A 2017-08-02 2018-08-02 核酸複合體 TW201909925A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-149761 2017-08-02
JP2017149761 2017-08-02

Publications (1)

Publication Number Publication Date
TW201909925A true TW201909925A (zh) 2019-03-16

Family

ID=65232882

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107126969A TW201909925A (zh) 2017-08-02 2018-08-02 核酸複合體

Country Status (2)

Country Link
TW (1) TW201909925A (ja)
WO (1) WO2019027015A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226332B (zh) * 2018-11-02 2025-05-09 阿布特斯生物制药公司 二价靶向缀合物
KR20210098477A (ko) * 2018-11-30 2021-08-10 쿄와 기린 가부시키가이샤 핵산 복합체
JP7676377B2 (ja) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ, インコーポレイテッド 補体成分C3 iRNA組成物およびその使用方法
MX2022013606A (es) * 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
AU2022325715A1 (en) * 2021-07-17 2024-02-01 Sirnaomics, Inc. Products and compositions
IL311146A (en) 2021-09-02 2024-04-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
EP4423273A1 (en) * 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
US20250115634A1 (en) * 2022-01-30 2025-04-10 Lnctac Co., Ltd. Ligand, method for preparing same, and use thereof
US12378558B2 (en) 2023-03-21 2025-08-05 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930393C (en) * 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
MX391815B (es) * 2011-11-18 2025-03-21 Alnylam Pharmaceuticals Inc AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR).
US9127276B2 (en) * 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10808246B2 (en) * 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3043827B1 (en) * 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
MX382900B (es) * 2013-12-12 2025-03-13 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
CA3012967A1 (en) * 2016-01-29 2017-08-03 Kyowa Hakko Kirin Co., Ltd. Nucleic acid conjugate
TW201730341A (zh) * 2016-02-05 2017-09-01 Kyowa Hakko Kirin Co Ltd 抑制補體b因子之表現之反義寡核苷酸
EP3498724B1 (en) * 2016-06-30 2023-06-21 Kyowa Kirin Co., Ltd. Nucleic acid complex

Also Published As

Publication number Publication date
WO2019027015A1 (ja) 2019-02-07

Similar Documents

Publication Publication Date Title
JP6853193B2 (ja) 核酸複合体
TW201909925A (zh) 核酸複合體
JP7022687B2 (ja) 核酸複合体
JPWO2017010575A1 (ja) β2GPI遺伝子発現抑制核酸複合体
US10487103B2 (en) Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
EP3888663A1 (en) Nucleic acid complex
TW201920668A (zh) 核酸複合體
JP2019024444A (ja) 核酸複合体
HK40059056A (en) Nucleic acid complex
CA3029508C (en) Nucleic acid conjugate